Target intelligence / Profile preview

MYC internal ribosome entry site (MYC IRES) (MYC IRES)

Target
MYC IRES
Molecular classification
Regulatory RNA element, Non-coding RNA, RNA
01

Overview

The MYC internal ribosome entry site (MYC IRES) is a highly structured RNA element located within the 5' untranslated region (UTR) of the MYC (c-Myc) mRNA (Stoneley et al., 2000, Nucleic Acids Research). It facilitates cap-independent translation initiation, allowing for the continued synthesis of the MYC oncoprotein even when global cap-dependent translation is suppressed, such as during cellular stress, hypoxia, or apoptosis (Spriggs et al., 2008, Genes & Development). This mechanism is crucial for the survival and proliferation of cancer cells within the often-hostile tumor microenvironment, where MYC acts as a master regulator of cell growth and metabolism (Dang, 2012, Cell). Because MYC is frequently overexpressed in a wide array of human malignancies, the MYC IRES represents an attractive therapeutic target for reducing oncogenic protein levels (Boussemart et al., 2014, Nature). Small molecules like CMLD010506 and various antisense oligonucleotides are being explored to disrupt the IRES structure or its interaction with IRES-transacting factors (ITAFs) such as PTBP1 and hnRNP K (Evans et al., 2003, Molecular and Cellular Biology; Hart et al., 2014, PNAS). However, targeting this element poses significant challenges, including the potential for off-target effects on other essential IRES-containing mRNAs and the risk of systemic toxicity due to MYC's critical role in normal tissue homeostasis and regeneration (Soucek et al., 2008, Nature).

Other names
c-Myc IRESMYC 5' UTR IRESInternal ribosome entry site of MYC mRNA
02

Mechanism of action

Inhibition of IRES-mediated translation initiation by disrupting RNA secondary structure or blocking the binding of IRES-transacting factors (ITAFs).

03

Biological functions

Translation initiationCap-independent translationProtein synthesis regulationCell cycle regulationCell proliferation
04

Disease associations

CancerLymphomaBreast cancerColorectal cancerProstate cancer
05

Safety considerations

Off-target effects on other IRES-containing mRNAsSystemic toxicity due to MYC's role in normal tissue regenerationPotential for compensatory cap-dependent translation
06

Interacting drugs

CMLD010506

3 more in the full profile.

07

Biomarkers

MYC protein levelsPTBP1 expressionhnRNP K expressionMYC mRNA levels

Beyond the preview

Go deeper on MYC internal ribosome entry site (MYC IRES) (MYC IRES).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MYC internal ribosome entry site (MYC IRES) (MYC IRES).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call